Author:
Saba Ludovic,Fu Chieh-Lin,Liang Hong,Chaulagain Chakra Pani
Reference34 articles.
1. The survival time of patients with plasmocytic myeloma;E E Osgood;Cancer Chemother Rep,1960
2. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT);Bgm Durie;Blood Cancer J,2020
3. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, openlabel, phase 3 trial;T Facon;Lancet Oncol,2021